Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 8/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 5/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 5/20 | 0.34 |
| ▸ | PRKDC | P78527 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.33 |
| ▸ | RAF1 | P04049 | 1/20 | 0.33 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 2/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CDK4 | P11802 | 1/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19627459 | 0.95 | MAP3K14 (0.39) | MAP3K14DYRK1AFGFR1FGFR2FGFR3 | |
| SCHEMBL16205525 | 0.95 | FGFR1 (0.36) | MAP3K14DYRK1AFGFR1FGFR2FGFR3 | |
| SCHEMBL16205382 | 0.94 | DYRK1A (0.36) | MAP3K14DYRK1AFGFR1FGFR2FGFR3 | |
| SCHEMBL16205576 | 0.91 | MAP3K14 (0.41) | MAP3K14DYRK1ATYK2CDK1 | |
| SCHEMBL19627454 | 0.91 | MAP3K14 (0.43) | MAP3K14TYK2 | |
| SCHEMBL19627460 | 0.89 | MAP3K14 (0.42) | MAP3K14TYK2 | |
| SCHEMBL16205383 | 0.89 | MAP3K14 (0.36) | MAP3K14DYRK1AMAP3K12 | |
| SCHEMBL16205343 | 0.89 | MAP3K14 (0.47) | MAP3K14 | |
| SCHEMBL16205613 | 0.87 | MAP3K14 (0.40) | MAP3K14TYK2 | |
| SCHEMBL16205625 | 0.87 | MAP3K14 (0.38) | MAP3K14DYRK1ATYK2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3209662-B1 | NEW COMPOUNDS AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-09 | — | — | EP | disclosed |
| US-10005776-B2 | Compounds as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-26 | — | — | US | disclosed |
| US-10005776-B2 | Compounds as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-26 | — | — | US | disclosed |
| US-20170334906-A1 | NEW COMPOUNDS AS NIK INHIBITORS | ARGENTA DISCOVERY 2009 LIMITED (GB) | 2017-11-23 | — | — | US | disclosed |
| US-20170334906-A1 | NEW COMPOUNDS AS NIK INHIBITORS | ARGENTA DISCOVERY 2009 LIMITED (GB) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005776-B2 | Compounds as NIK inhibitors | MAP3K14, MAP3K15, MAP3K12 | MAP3K14 1/4885DYRK1A 1491/4885FGFR1 1965/4885 |
| US-20170334906-A1 | NEW COMPOUNDS AS NIK INHIBITORS | MAP3K14, IKBKG, MAP3K15 | MAP3K14 1/4885DYRK1A 1234/4885FGFR1 2056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.